MX2023014228A - Vector lentiviral. - Google Patents

Vector lentiviral.

Info

Publication number
MX2023014228A
MX2023014228A MX2023014228A MX2023014228A MX2023014228A MX 2023014228 A MX2023014228 A MX 2023014228A MX 2023014228 A MX2023014228 A MX 2023014228A MX 2023014228 A MX2023014228 A MX 2023014228A MX 2023014228 A MX2023014228 A MX 2023014228A
Authority
MX
Mexico
Prior art keywords
vector
lentiviral particles
linear dna
closed linear
production
Prior art date
Application number
MX2023014228A
Other languages
English (en)
Spanish (es)
Inventor
Sarah Moore
Thomas Adie
Gonzalez Maria Barreira
Original Assignee
Touchlight Ip Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2108176.5A external-priority patent/GB202108176D0/en
Priority claimed from GBGB2207077.5A external-priority patent/GB202207077D0/en
Application filed by Touchlight Ip Ltd filed Critical Touchlight Ip Ltd
Publication of MX2023014228A publication Critical patent/MX2023014228A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051Methods of production or purification of viral material
    • C12N2740/15052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15061Methods of inactivation or attenuation
    • C12N2740/15062Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16041Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/20011Rhabdoviridae
    • C12N2760/20211Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/50Vectors for producing vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/50Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of Eletrric Generators (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Detail Structures Of Washing Machines And Dryers (AREA)
MX2023014228A 2021-06-08 2022-06-08 Vector lentiviral. MX2023014228A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108176.5A GB202108176D0 (en) 2021-06-08 2021-06-08 Vector
GBGB2207077.5A GB202207077D0 (en) 2022-05-14 2022-05-14 Vector
PCT/GB2022/051437 WO2022258967A1 (en) 2021-06-08 2022-06-08 Lentiviral vector

Publications (1)

Publication Number Publication Date
MX2023014228A true MX2023014228A (es) 2024-01-25

Family

ID=82067426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014228A MX2023014228A (es) 2021-06-08 2022-06-08 Vector lentiviral.

Country Status (10)

Country Link
US (1) US20250122528A1 (https=)
EP (1) EP4352238A1 (https=)
JP (1) JP2024520797A (https=)
KR (1) KR20240024807A (https=)
AU (1) AU2022289260A1 (https=)
BR (1) BR112023025408A2 (https=)
CA (1) CA3222751A1 (https=)
IL (1) IL308705A (https=)
MX (1) MX2023014228A (https=)
WO (1) WO2022258967A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025076341A1 (en) * 2023-10-05 2025-04-10 Janssen Biotech, Inc. Improved methods in lentiviral manufacturing for production of car-t cell drug products

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834256A (en) 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
GB0901593D0 (en) 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
GB201502645D0 (en) 2015-02-17 2015-04-01 Touchlight Genetics Ltd Method
DK3500682T3 (da) 2016-08-16 2020-08-24 Touchlight Ip Ltd Fremstilling af lukket, lineært dna
KR20190089988A (ko) * 2016-12-06 2019-07-31 블루버드 바이오, 인코포레이티드. I형 점액다당류증에 대한 유전자 요법

Also Published As

Publication number Publication date
WO2022258967A1 (en) 2022-12-15
JP2024520797A (ja) 2024-05-24
IL308705A (en) 2024-01-01
CA3222751A1 (en) 2022-12-15
KR20240024807A (ko) 2024-02-26
AU2022289260A1 (en) 2023-12-07
EP4352238A1 (en) 2024-04-17
WO2022258967A9 (en) 2023-03-02
WO2022258967A8 (en) 2023-11-23
BR112023025408A2 (pt) 2024-02-27
US20250122528A1 (en) 2025-04-17

Similar Documents

Publication Publication Date Title
CL2022001372A1 (es) Construcciones para terapia génica con microdistrofina y uso de las mismas.
MX2023014228A (es) Vector lentiviral.
CY1124518T1 (el) Μεταλλαγες πρωτεϊνης φακελου hiv που σταθεροποιουν το τριμερες
CL2019003561A1 (es) Agentes potenciadores para la transfección celular mejorada y/o la producción del vector raav.
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
CO6331346A2 (es) Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo
MX2021006359A (es) Vectores virales de vaa y sus usos.
Berinde Approximating Fixed Points of Implicit Almost Contractions FULL TEXT
MX2012001075A (es) Vectores lentivirales pseudotipificados con una glicoproteina de envoltura de virus sindbis.
MX2021000153A (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.
CL2020001135A1 (es) Vectores.
CL2019000655A1 (es) Nuevo sitio de inserción orf70 de ehv.
CO2018011663A2 (es) Nticuerpos anti-basigin humanizados y uso de los mismos
Kibe et al. Quantum Thermodynamics of Holographic Quenches and Bounds on the Growth of Entanglement from the Quantum Null Energy Condition
ECSP23024245A (es) Construcciones de ácido nucleico, vectores virales y partículas virales
CL2023000919A1 (es) Vector neurod1
CO2024002241A2 (es) Modificación de linfocitos t gamma delta y composiciones de estos
Kovacsics et al. Beautiful pairs
Krishna et al. Enumeration of N-rooted maps using quantum field theory
PE20211731A1 (es) Anticuerpo monoclonal que se une especificamente al antigeno cd20
DE60238773D1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
Jóźwikowski et al. Bundle-theoretic methods for higher-order variational calculus
Rush On order ideals of minuscule posets III: The CDE property
AR121806A1 (es) Uso de vectores virales para la producción de vacunas contra coronavirus
Fine et al. Corrigiendo a Stiglitz: de la información al poder en el mundo del desarrollo